TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06035354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection every 2 weeks.
Study: NCT06282926

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography assessment
Description: Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography assessment
Description: Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound.
Study: NCT04652479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avexitide
Description: Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avexitide
Description: Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
Study: NCT06390969

Intervention type: OTHER
Intervention: Survey
Description: Cross-sectional online survey
Study: NCT04809974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niagen
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
Study: NCT05436847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Neurodevelopmental treatment- age appropriate
Study: NCT05891301

Intervention type: OTHER
Intervention: Questionnaires set
Description: The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
Study: NCT02871232

Intervention type: OTHER
Intervention: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion

Intervention type: OTHER
Intervention: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion
Study: NCT02512432

Intervention type: DEVICE
Group type: OTHER
Intervention: INTACS
Description: asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
Study: NCT03787628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 600 mg
Description: CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
Study: NCT04591925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Device insulin infusion devcie
Description: Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigative insulin infusion devcie
Description: Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
Study: NCT06195995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation-true stimulus
Description: Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
Study: NCT06242223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal HIIT
Description: multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional HIIT
Description: conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
Study: NCT06103487

Intervention type: GENETIC
Intervention: No Intervention
Description: Observational study
Study: NCT05366478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocytes (TILs)
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
Study: NCT06143124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Subcitrate
Description: shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
Study: NCT05235685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical air
Description: Exercise under medical air, both arms exposed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air
Description: Exercise under medical air, both arms exposed.
Study: NCT05027685

Intervention type: DEVICE
Intervention: The Paradise Ultrasound Renal Denervation System
Description: The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
Study: NCT05235685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Exercise under hyperoxia, only experimental arm exposed.
Study: NCT01295099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5- fluorouracil
Description: 5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: after complete excision of keloid they have a single session of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: TAC 10mg in 1ml injected intralesional
Study: NCT05890404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Materials Only
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Direct Training
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-Affirmative CBT Training: Local Supervision
Description: Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center.
Study: NCT06519448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 miligrams (mg)
Description: Use of empagliflozin 10 mg daily for 12 months.
Study: NCT06318377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut group
Description: These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
Study: NCT05224245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE Prime XL Transfemoral Aortic Valve System
Description: ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
Study: NCT05737004

Intervention type: DIAGNOSTIC_TEST
Intervention: functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II
Description: fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .

Intervention type: DIAGNOSTIC_TEST
Intervention: functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II
Description: fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
Study: NCT06093152

Intervention type: DRUG
Intervention: Salbutamol
Description: Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
Study: NCT04590209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
Study: NCT06303128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 MG
Description: Liquid amoxicillin 250mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given prior to amoxicillin 250mg in one-dose group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 62.5mg
Description: Given first in two-dose group, liquid amoxicillin 62.5mg PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 187.5mg
Description: Given second in two-dose group, liquid amoxicillin 187.5mg PO
Study: NCT06238310

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comparison of two external marker substance for measuring glomerular filtration rate
Description: Two external marker substance compares for measuring GFR.
Study: NCT06265623

Intervention type: OTHER
Intervention: No active intervention, but observational follow-up
Description: Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years

Intervention type: OTHER
Intervention: No active intervention, but observational follow-up
Description: Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
Study: NCT05932264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + Fluzoparib
Description: Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + Fluzoparib + Adebrelimab
Description: Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
Study: NCT05707481

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Pharmacist-Led Educational Intervention
Description: Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
Study: NCT05464498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Tissue Collagen Medical Device
Description: MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks).

Intervention type: OTHER
Group type: OTHER
Intervention: eccentric strengthening protocol
Description: Group B which, will implement only physiotherapy (eccentric strengthening protocol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric strengthening protocol
Description: Group B which, will implement only physiotherapy (eccentric strengthening protocol)
Study: NCT05883046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance-Enhancing Substances
Description: All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance-Enhancing Substances
Description: All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance-Enhancing Substances
Description: All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
Study: NCT05450133

Intervention type: OTHER
Intervention: Systemic inflammatory index
Description: neutrophil count x platelet count/lymphocyte count

Intervention type: OTHER
Intervention: Systemic inflammatory index
Description: neutrophil count x platelet count/lymphocyte count

Intervention type: OTHER
Intervention: Systemic inflammatory index
Description: neutrophil count x platelet count/lymphocyte count

Intervention type: OTHER
Intervention: BASDAI
Description: Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.

Intervention type: OTHER
Intervention: BASDAI
Description: Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.

Intervention type: OTHER
Intervention: ASDAS-ESR
Description: The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
Study: NCT05883046

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline (Control)
Description: No supplement conditions
Study: NCT06414161

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mix of (green tea and peppermint)
Description: Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mix of (green tea and peppermint)
Description: Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract.
Study: NCT05026541

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nap Practitioners
Description: Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoonya Meditation
Description: This is a 15 minute meditation, described as a process of conscious non-doing.
Study: NCT04610736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Suspension
Description: One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days